文献速递眼整形与眼眶

眼眶附属器肿瘤中的基因融合

Gene Fusions in Ocular Adnexal Tumors.
PubMed 文献 · Am J Ophthalmol · 2020-08-13

本文为视角性综述,聚焦泪腺及原发性眼眶和眼附属器软组织肿瘤中的基因融合及其致病机制与检测方法。文章指出,FISH 与二代测序的广泛应用使分子遗传学成为组织学和免疫表型重叠肿瘤的诊断金标准,基因融合还具有预后意义并可指导靶向治疗。

要点

  • 分子遗传学方法已成为组织学和免疫表型重叠肿瘤(如小圆蓝细胞肿瘤)的诊断金标准。
  • 经典基因融合可促成敏感特异的免疫组化标志物,如孤立性纤维性肿瘤中的 STAT6。
  • 基因融合具预后意义,如肺泡型横纹肌肉瘤中 PAX3-FOXO1 融合提示预后不良;NTRK 融合阳性癌症可用 TRK 抑制剂靶向治疗。

核心结论

  • 包括眼附属器在内的多种肿瘤中反复发现的基因融合,加深了对这些肿瘤分子机制的理解,并革新了其诊断、预后评估和治疗策略。

研究设计与样本

  • 本文为视角性综述,聚焦泪腺及原发性眼眶和眼附属器软组织肿瘤中的基因融合、致病机制与基因融合检测方法,并基于新兴分子遗传学数据重新审视眼附属器肿瘤的诊断、预后和治疗路径。

主要发现

  • 荧光原位杂交和二代测序在病理实践中的广泛应用,使多种肿瘤中反复出现的基因重排和融合得以鉴定。
  • 分子遗传学方法已成为组织学和免疫表型重叠肿瘤(如小圆蓝细胞肿瘤)诊断的金标准。
  • 经典基因融合的鉴定促成了敏感且特异的免疫组化标志物的开发,如孤立性纤维性肿瘤中的 STAT6。
  • 基因融合具有预后意义,如肺泡型横纹肌肉瘤中 PAX3-FOXO1 融合提示预后不良。
  • 基因融合作为肿瘤驱动机制的识别促成了美国食品药品监督管理局批准的靶向治疗,如针对 NTRK 融合阳性癌症的 TRK 抑制剂。

临床怎么用

  • 在组织学和免疫表型重叠的眼附属器肿瘤(如小圆蓝细胞肿瘤)诊断中,应采用分子遗传学方法(如 FISH、二代测序)作为金标准。
  • 可利用基因融合衍生的免疫组化标志物(如 STAT6)辅助诊断孤立性纤维性肿瘤。
  • 检测 PAX3-FOXO1 融合可用于肺泡型横纹肌肉瘤的预后评估。
  • 识别 NTRK 融合可指导 TRK 抑制剂靶向治疗的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To highlight the increasing importance of gene fusions in the diagnosis, prognosis, and therapy of ocular adnexal tumors. DESIGN: Perspective. METHODS: A focused review of gene fusions, their pathogenic mechanism, and gene fusion detection methods in lacrimal gland and primary orbital and ocular adnexal soft tissue tumors; reappraisal of diagnostic, prognostic, and therapeutic approach to ocular adnexal tumors in light of emerging molecular genetic data. RESULTS: The widespread implementation of fluorescence in situ hybridization and next-generation sequencing methods in pathology practice has led to identification of recurrent gene rearrangements and fusions in a variety of tumors. As a result, molecular genetic methods have become the gold standard for diagnosis of tumors with overlapping histology and immunophenotype, such as small round blue cell tumors. Identification of canonic gene fusions has led to development of sensitive and specific immunohistochemical markers, such as STAT6 in solitary fibrous tumor. In addition to diagnostic accuracy, gene fusions have prognostic implications, such as unfavorable prognosis of PAX3-FOXO1 fusion in alveolar rhabdomyosarcoma. Finally, recognition of gene fusions as a driving mechanism in neoplasia has led to development of U.S. Food and Drug Administration-approved targeted therapies, such as TRK inhibitors for NTRK fusion-positive cancers. CONCLUSION: The discovery of recurrent gene fusions in various tumors, including those involving ocular adnexa, has led to a deeper insight into the molecular mechanisms of these neoplasms, revolutionizing our approach to their diagnosis, prognostication, and therapy.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Milman T, Ida CM, Zhang PJL, et al. Gene Fusions in Ocular Adnexal Tumors. Am J Ophthalmol. 2020. PMID: 32800827. doi:10.1016/j.ajo.2020.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。